Skip to main content

Topic

Biological Products

18 published works

  1. As Prescribed

    The European Commission Proposes Biotech Act to Support Development of Biotech Products

    By Morgan Lewis

    At the end of 2025, as part of a bundle of measures to make the EU health sector more innovative, competitive and resilient, the European Commission proposed the EU Biotech…

  2. BioSlice Blog

    Can a chemically synthesised medicine be authorised as a generic of a biological medicine? And who can challenge this?

    By Alexander Roussanov, Libby Amos-Stone, Heba Jalil

    On 23 October 2025, Advocate General (“AG”) Emiliou delivered his opinion in Case C-118/24: Laboratoires Eurogenerics and Theramex France.[1] The AG opines on three key questions regarding the use of the…

  3. Big Molecule Watch

    Eli Lilly Files Suit Challenging the FDA’s Drug Classification of Retatrutide

    By Daniel Farraye|Brian Burgess

    On September 3, 2024, Eli Lilly filed a complaint against the FDA in the District Court for the Southern District of Indiana pursuing the latest challenge to the FDA’s application…

  4. BioSlice Blog

    Evaluation of New Active Substance Status for Biological Products in the EU

    By Arnold & Porter, Alexander Roussanov, Sofia Wilson

    On 18 November 2022, the European Medicines Agency (EMA) published a draft reflection paper (Paper) for public consultation on the criteria for the evaluation of new active substance (NAS) status…

  5. Nano and Other Emerging Chemical Technologies Blog

    FDA Publishes Final Guidance for Industry on Drug Products, Including Biological Products, that Contain Nanomaterials

    By Lynn L. Bergeson, Carla N. Hutton

    The U.S.  Food and Drug Administration (FDA) announced on April 22, 2022, the availability of a final guidance for industry entitled “Drug Products, Including Biological Products, that Contain Nanomaterials.” 87…

  6. Big Molecule Watch

    Purple Book Updates

    By Alexandra Valenti

    In 2021, the FDA’s Purple Book went live, providing a searchable database of licensed biological products, including the patent information provided to biosimilar applicants during the patent dance.  Pursuant to a law enacted…

  7. China Law Insight

    进口生物物品的合规管理

    By King & Wood

    本文将梳理生物物品进口的监管要求,协助生物医药企业进行进口生物物品的合规管理。

  8. Big Molecule Watch

    FDA Issues Final Definition for “Biological Product”

    By Big Molecule Watch

    The FDA recently issued a final rule regarding the definition of “biological product,” amending its previous definition.  The statutory definition of “biological product” included “protein (except any chemically synthesized polypeptide),”…

  9. Big Molecule Watch

    FDA Launches First Phase of Searchable Purple Book Website

    By Big Molecule Watch

    Today the FDA launched a partial searchable version of the “Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations”, colloquially known as the “Purple Book“.…

  10. Biosimilars Law Bulletin

    FDA Proposes Amendment to the Definition of “Biological Product”

    By Seth E. Cockrum

    The FDA recently proposed an amendment to its regulations defining the term “biological product.”  The proposed amendment incorporates changes made by the Biologics Price Competition and Innovation Act (BPCIA) into the…